- Home
- STHO vs ADAG Comparison
STHO vs ADAG Comparison
Compare STHO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- ADAG
- Stock Information
- Founded
- STHO N/A
- ADAG 2011
- Country
- STHO United States
- ADAG China
- Employees
- STHO N/A
- ADAG N/A
- Industry
- STHO Real Estate
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- ADAG Health Care
- Exchange
- STHO Nasdaq
- ADAG Nasdaq
- Market Cap
- STHO 89.7M
- ADAG 91.4M
- IPO Year
- STHO N/A
- ADAG 2021
- Fundamental
- Price
- STHO $7.86
- ADAG $1.94
- Analyst Decision
- STHO
- ADAG Strong Buy
- Analyst Count
- STHO 0
- ADAG 1
- Target Price
- STHO N/A
- ADAG $8.00
- AVG Volume (30 Days)
- STHO 200.8K
- ADAG 99.4K
- Earning Date
- STHO 08-05-2025
- ADAG 07-24-2025
- Dividend Yield
- STHO N/A
- ADAG N/A
- EPS Growth
- STHO N/A
- ADAG N/A
- EPS
- STHO N/A
- ADAG N/A
- Revenue
- STHO $113,297,000.00
- ADAG $103,204.00
- Revenue This Year
- STHO N/A
- ADAG $6,488.89
- Revenue Next Year
- STHO N/A
- ADAG $57.50
- P/E Ratio
- STHO N/A
- ADAG N/A
- Revenue Growth
- STHO N/A
- ADAG N/A
- 52 Week Low
- STHO $6.06
- ADAG $1.33
- 52 Week High
- STHO $14.50
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- STHO 58.31
- ADAG 53.76
- Support Level
- STHO $7.60
- ADAG $1.74
- Resistance Level
- STHO $8.19
- ADAG $2.10
- Average True Range (ATR)
- STHO 0.28
- ADAG 0.10
- MACD
- STHO -0.00
- ADAG -0.01
- Stochastic Oscillator
- STHO 64.71
- ADAG 55.56
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.